Genmab A/S
ISIN US3723032062
|WKN A1WZYB
Market cap (in EUR)
17,616 m
Country
Denmark
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Denmark
Financials
Key metrics
| Market capitalisation, EUR | 17,616 m |
| EPS, EUR | 1.10 |
| P/B ratio | 3.3 |
| P/E ratio | 25.8 |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 3,308 m |
| Net income, EUR | 856 m |
| Profit margin | 25.89% |
What ETF is Genmab A/S in?
There are 6 ETFs which contain Genmab A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Genmab A/S is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| WisdomTree Megatrends UCITS ETF USD | 0.03% | Equity World Social/Environmental Innovation | 60 |
| Invesco Nasdaq Biotech UCITS ETF | 0.16% | Equity United States Health Care Biotech | 439 |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.16% | Equity United States Health Care Biotech | 72 |
| iShares Nasdaq US Biotechnology UCITS ETF | 0.16% | Equity United States Health Care Biotech | 1,049 |
| First Trust NYSE Arca Biotechnology UCITS ETF Acc | 3.55% | Equity United States Health Care Biotech | 16 |
| WisdomTree BioRevolution UCITS ETF USD Acc | 0.45% | Equity World Health Care Social/Environmental Biotech | 35 |
Savings plan offers
Here you can find information about the savings plan availability for the stock. You can use the table to compare savings plan offers for the selected savings rate.
Detailed comparison of all offers
Source: justETF Research; as of 10/2026. The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of stock savings plans. The number of stock savings plans is rounded. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information. (en-IT)